Abstract
Alzheimer's disease (AD) is the most prevalent type of dementia. Despite considerable advances in diagnostic accuracy, diagnostic procedures that are easily accessible are still sorely needed. Blood biomarkers are therefore in the focus of research. Platelets contain a high concentration of the amyloid precursor protein (APP), which has been mentioned as a potentially useful diagnostic marker. The aim of the present study was to analyze various cell adhesion molecules (CAMs), cytokines, growth factors, and matrix metalloproteinases (MMPs) in platelets of AD and mild cognitively impaired (MCI) patients as compared to healthy controls. Our data show a significant decrease in the levels of epidermal growth factor (EGF) and of MMP-2 in platelets of AD patients and decreased levels of MMP-2 in MCI. The APP ratio was slightly but not significantly decreased in AD patients, whereas CD40L and serotonin were unchanged. Our findings demonstrate specific changes in AD platelets. Whether these biomarkers can be established as potential early diagnostic biomarkers for AD remains to be established in longitudinal studies.
Keywords: Alzheimer, biomarker, platelets, diagnosis, EGF, MMP-2, Immunohistochemistry, Serotonin
Current Alzheimer Research
Title:Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients
Volume: 9 Issue: 8
Author(s): Tanja Hochstrasser, Daniela Ehrlich, Josef Marksteiner, Barbara Sperner-Unterweger and Christian Humpel
Affiliation:
Keywords: Alzheimer, biomarker, platelets, diagnosis, EGF, MMP-2, Immunohistochemistry, Serotonin
Abstract: Alzheimer's disease (AD) is the most prevalent type of dementia. Despite considerable advances in diagnostic accuracy, diagnostic procedures that are easily accessible are still sorely needed. Blood biomarkers are therefore in the focus of research. Platelets contain a high concentration of the amyloid precursor protein (APP), which has been mentioned as a potentially useful diagnostic marker. The aim of the present study was to analyze various cell adhesion molecules (CAMs), cytokines, growth factors, and matrix metalloproteinases (MMPs) in platelets of AD and mild cognitively impaired (MCI) patients as compared to healthy controls. Our data show a significant decrease in the levels of epidermal growth factor (EGF) and of MMP-2 in platelets of AD patients and decreased levels of MMP-2 in MCI. The APP ratio was slightly but not significantly decreased in AD patients, whereas CD40L and serotonin were unchanged. Our findings demonstrate specific changes in AD platelets. Whether these biomarkers can be established as potential early diagnostic biomarkers for AD remains to be established in longitudinal studies.
Export Options
About this article
Cite this article as:
Hochstrasser Tanja, Ehrlich Daniela, Marksteiner Josef, Sperner-Unterweger Barbara and Humpel Christian, Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251156
DOI https://dx.doi.org/10.2174/156720512803251156 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Serum Albumin Concentration and Cognitive Impairment
Current Alzheimer Research A Synthesis of Functional Neuroimaging in the Frontal Variant of Frontotemporal Dementia
Current Medical Imaging Natural Product Formulations for the Prevention and Treatment of Alzheimer's disease: A Patent Review
Recent Patents on Drug Delivery & Formulation Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Stroke History is an Independent Risk Factor for Poor Prognosis in Ischemic Stroke Patients: Results from a Large Nationwide Stroke Registry
Current Neurovascular Research Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews Predicted Fold for the Abri Amyloid Subunit: A Model for Amyloidogenesis in Familial British Dementia
Protein & Peptide Letters SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Oxidant/Antioxidant Imbalance and the Risk of Alzheimer's Disease
Current Alzheimer Research A Review of Premature Frailty in HIV-Infected Persons; Another Manifestation of HIV-Related Accelerated Aging
Current Aging Science